The new standard in molecular testing.
Ready-to-run or custom PCR solutions that give you more biology, more range, more sensitivity, and more certainty, all from a single assay. Built for AML, CML, and beyond.
Ancora hematologic malignancy measurement solutions give high precision at PCR-level simplicity.
Ancora heme oncology solutions are built for single-molecule detection and consistent results no matter when or where the measurement is taken, while offering the sensitivity to detect residual disease other tests may miss — essential for evaluating molecular response, resistance, or remission. Get more biology from even the most precious of samples: Resolve fusion partners, phase co-mutations, and deliver direct quantification, all without standard curves, dead volume, or sample waste.
Built for hematologic oncology labs and pharma partners who don’t want to choose between speed, sensitivity, and completeness. Ancora assays are a complete solution that can be run in hours, not days, with the flexibility to run one sample or a full batch and get more from every test.
Results you can count on
Each single molecule is counted individually so you get consistent, true, and reproducible results every time with MRD-grade sensitivity.
Get the full biological picture from every precious sample
Resolve more targets, phase co-mutations without knowing exact breakpoints, and get more of the biology behind them, in a single assay.
Expand capability without expanding cost or complexity
Data on-demand, all on one system ready for DNA, RNA or methylation analysis as your menu grows.
Multiple kits, one flexible & high capability workflow
Quantify 4 BCR::ABL1 transcripts plus ABL1 beyond MR5.0
Detect KMT2A rearrangements for MRD tracking
Delivers the depth of RNA with the standardized precision of absolute counting of NPM1 mutations
Simultaneously detect KIT D816V down to 0.015% VAF and KIT WT
Count all three canonical PML::RARA isoforms plus ABL1
Perform TKI resistance testing following a positive BCR::ABL1 result
Don’t see what you’re
looking for?
Tell us what you need and we'll tell you what it would take to get there with Ancora solutions and Countable PCR.
- Assay services, custom targets, inputs, and indications not covered by the current available kits
- Sensitivity, input, or workflow roadblocks in your existing assays
- Collaborations & co-development
- Instrument access & demo options
The technology behind Ancora Heme Oncology Solutions.
A brief introduction to the simplicity and power of Countable PCR.
30M
compartments
100%
of sample analyzed
<1%
CV across runs
What users say about the Ancora solutions.
"In our benchmarking work, the biggest difference we saw with Countable PCR was the precision. We measured coefficients of variation, which were substantially tighter than what we see with conventional FDA-approved RT-PCR. When you're tracking a patient's molecular response over time, that kind of reproducibility matters."
Pamela Ward, PhD
Associate Professor Clinical Pathology
University of Southern California
“Fulfilling exhaustive RT-PCR requests for KMT2A and other leukemia fusions is often hindered by limited sample volumes. Countable PCR overcomes this barrier through highly multiplexed, high-throughput assays. By seamlessly handling both low-volume inputs for initial multi-target screening and high-volume inputs for precise disease monitoring of a specific target, it offers an exceptionally versatile diagnostic platform for us and our needs.”
Dongbin Xu, PhD
Vice President, Laboratory DirectorAssociate Professor Clinical Pathology
HematoLogics, Inc.
Consistent BCR::ABL1 quantification across four transcripts in one reaction
Read Application Note
Evaluation of a deep-sampling PCR assay for KIT D816V detection at ultra-low variant allele frequencies
View PosterExpand capability without expanding complexity.
An end-to-end solution
A familiar PCR workflow with single-molecule counting: superior precision, reproducibility, sensitivity, and linear performance across a wide dynamic range.
~3 hrs
No need to choose between speed, sensitivity, and completeness. Results in as little as 3 hrs.
6-log
Linear at R²=0.9999.
Ancora Heme Oncology
Ready to run or custom assays for heme oncology applications
Get Access Today
Proof-of-concept studies, sample to data.
Countable PCR
Custom programs built around a lab's budget and timeline are available to get instrument access.
Automated analysis
No raw data to process.
Ancora BCR::ABL1 Assay
The Ancora BCR::ABL1 assay provides a single-tube solution that does not require separate assays for quantification and detection. The Ancora BCR::ABL1 assay quantifies all four transcripts, e14a2, e13a2, e1a2, and e19a2, alongside the ABL1 reference in a single closed reaction, directly from extracted RNA, with no switch between baseline and monitoring. Sensitivity scales with input, reaching 0.0007% at one million ABL1 copies, beyond MR5.0, while direct single-molecule counting delivers under 1% CV across days, operators, and sites, with automated reporting and no standard curves to drift between runs.
- Beyond MR5.0 Sensitivity: 0.0007% IS at ≥1M ABL1
- High Color Multiplex Detection: One reaction maintains linear quantification across four fusion and ABL1 transcripts
- Reproducibility: Direct single-molecule counting delivers <1% CV across days, operators, and sites
- Standardized reporting: Get automated reports from direct counts, including %IS, without per-run standard curves or drifting laboratory calibrations
- BK0005 Ancora BCR::ABL1 BundleThis complete 48-reaction solution includes two kits and a software module: (1) a multiplexed 6-color assay that detects four major BCR::ABL1 fusion isoforms — e14a2, e13a2 (p210), e1a2 (p190), and e19a2 (p230) against reference gene ABL1 in a single RNA-input reaction with Imaging Control included; (2) Countable PCR consumables and matrix reagents; and (3) a software module for data collection and reporting.
For Research Use Only. Not for use in diagnostic procedures.
Request more information on Ancora Oncology Assays.
We'll send pricing and availability for Ancora BCR::ABL1 Kit.
Ancora KMT2A-r Assay
The Ancora KMT2A-r assay covers 18 transcripts across the six most common fusion partners, roughly 90-95% of cases, in a kitted solution of multiplex RNA reactions that identifies the fusion at diagnosis and tracks the same marker through MRD. A fusion is called only when the KMT2A side and partner side of the junction appear on the same molecule, with no false positives. Designed for 10⁻⁵ sensitivity, in an assay built to make the most of limited input, accommodating roughly 20 ng to 1 µg of RNA with no dead volume, particularly valuable for precious pediatric samples.
- Comprehensive multiplex coverage: One assay detects 18 fusion transcripts across the 6 most common partners — roughly 90–95% of cases
- Diagnosis through MRD: The same assay identifies the fusion at diagnosis and monitors it through MRD — no per-patient assay redesign required
- Make the most of limited samples: Accommodates ~20 ng to 1 µg of RNA, with no dead volume and flexible load up to 35 µL — designed to make the most of precious pediatric samples
- BK0006 Ancora KMT2A-r BundleThis complete 48-reaction solution includes two kits and a software module: (1) Two-tube multiplexed 5-color assay that detects 18 fusion transcripts across 6 common partners- MLLT3, AFF1, MLLT4, ELL, MLLT10, and MLLT1 against reference gene ABL1 in an RNA-input reaction with Imaging Control included; (2) Countable PCR consumables and matrix reagents; and (3) a software module for data collection and reporting.
For Research Use Only. Not for use in diagnostic procedures.
Request more information on Ancora Oncology Assays.
We'll send pricing and availability for Ancora KMT2A-r Assay.
Ancora NPM1 Mutation Assay
The Ancora NPM1 RNA assay captures Types A, B, and D alongside an ABL1 reference in a single reaction, directly from RNA rather than genomic DNA, aligning with the latest clinical consensus, including 2025 ELN guidelines. By isolating molecules across 30 million compartments, it replaces standard curves entirely with direct physical counting, going from extracted RNA to absolute molecular counts in a single Countable PCR workflow.
- RNA-driven MRD sensitivity: Detect lower-level NPM1 mutations by targeting highly expressed RNA transcripts
- Targeted coverage of major variants in a single assay:
Cover NPM1 Types A, B and D plus ABL1 in one reaction - Simplified workflow, fast turnaround: Go from extracted RNA to absolute molecular counts in one RT-PCR workflow
- BK0007 Ancora NPM1 Mutation BundleThis complete 48-reaction solution includes two kits and a software module: (1) One tube multiplexed 4-color assay that detects the three most common NPM1 mutations (Type A, Type B, and Type D) against reference gene ABL1 in a single RNA-input reaction with Imaging Control included; (2) Countable PCR consumables and matrix reagents; and (3) a software module for data collection and reporting.
For Research Use Only. Not for use in diagnostic procedures.
Request more information on Ancora Oncology Assays.
We'll send pricing and availability for Ancora NPM1 Mutation Assay.
Ancora KIT D816V Assay
Rare-variant detection shouldn't mean choosing between sensitivity and workflow simplicity. The Ancora KIT D816V assay resolves both, detecting the mutation down to 0.015% VAF alongside KIT WT in one reaction, across a DNA input range wide enough to skip upfront normalization entirely. No batching, no dead volume, no standard curves, just a single tube delivering sub-1% CV across sites and operators.
- Ultra-low sensitivity: Detect KIT D816V consistently down to 0.015% VAF in a single reaction, with minimal background
- Sample input flexibility: Wide input tolerance supports robust rare-variant detection, skip upfront normalization across 5 - 2,000 ng DNA inputs
- Simplified multiplex workflow: Consolidates multiple reactions into a single well, no batching, no dead volume, no standard curves, while delivering <1% CV across sites and operators
- BK0008 Ancora KIT D816V BundleThis complete 48-reaction solution includes two kits and a software module: (1) One-tube multiplexed 2-color assay that detects KIT D816V mutation and wild-type allele in a DNA-input reaction with Imaging Control included; (2) Countable PCR consumables and matrix reagents; and (3) a software module for data collection and reporting.
For Research Use Only. Not for use in diagnostic procedures.
Request more information on Ancora Oncology Assays.
We'll send pricing and availability for Ancora Kit D816V Assay.
Ancora PML::RARA Assay
Deep APL monitoring should not have to require running three separate assays or rebuilding a standard curve every time. The Ancora PML::RARA RNA assay counts all three canonical isoforms, bcr1, bcr2, bcr3, alongside ABL1 in a single 4-plex reaction, with results reporting directly as a PML::RARA/ABL1 ratio, no curve required. Designed for 10⁻⁵ sensitivity across at least 5 logs of dynamic range, it stays comparable run to run without recalibration.
- Complete isoform coverage: Single-tube 4-plex counts bcr1, bcr2, and bcr3 independently alongside ABL1
- Ultra-low sensitivity: Designed for 10⁻⁵ sensitivity with a dynamic range spanning at least 5 logs
- Standardization built in: Single molecule counting with no standard curves to build, run, or maintain
- Simplified data interpretation: Automated reporting with PML::RARA/ABL1 ratio
- BK0009 Ancora PML::RARA BundleThis complete 48-reaction solution includes two kits and a software module: (1) a multiplexed 4-color assay that detects three major PML::RARA fusion isoforms associated with t(15;17) (bcr1, bcr2, and bcr3) against reference gene ABL1 in a single RNA-input reaction with Imaging Control included; (2) Countable PCR consumables and matrix reagents; and (3) a software module for data collection and reporting.
For Research Use Only. Not for use in diagnostic procedures.
Request more information on Ancora Oncology Assays.
We'll send pricing and availability for Ancora PML::RARA Assay.
Ancora ABL1 TKI Resistance Mutation Phasing Assay
Detection of a positive BCR::ABL1 result should not require switching platforms to dig deeper. The Ancora ABL1 TKI Resistance Mutation assay reflexes straight from the same RNA into resistance testing, quantifying T315I, E255K, and E255V against their wild-type counterparts in a single six-color reaction, with sensitivity down to 0.1-1% mutant transcript fraction, below where sequencing first detects an emerging clone. Because each target is detected individually, the assay can also resolve whether two mutations occur on the same molecule or in separate clones, a distinction that changes whether a patient has a compound resistance mutation.
- In-house reflex testing: Reflex from a rising BCR::ABL1 result straight into mutation testing, same RNA, same platform, no send-out
- Ultra-low sensitivity: Designed to detect mutant transcript fractions as low as 0.1-1%, below where sequencing first sees an emerging clone
Complete resistance panel: T315I, E255K, and E255V, each counted against its wild-type counterpart alongside an ABL1 reference, in a single six-color reaction - Cis/trans phasing: Resolves whether two mutations sit on the same molecule (a compound mutant) or occur in separate clones, a distinction sequencing cannot make
- Information coming soon
For Research Use Only. Not for use in diagnostic procedures.
Request more information on Ancora Oncology Assays.
We'll send pricing and availability for Ancora ABL1 TKI Resistance Mutation Phasing Assay.
